AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$BSX

Boston Scientific Q3 Earnings Call Highlights

Boston Scientific (BSX) reported Q3 adjusted gross margin at 68.0%, down 300 basis points YoY. It forecasts 2026 organic revenue growth of 3.75%, adjusted EPS of $3.16-$3.18, and $3.6B in free cash flow. Challenges in EP and WATCHMAN businesses are expected to persist into 2027, with recovery anticipated in 2028. A restructuring program aims to generate $500M in savings over three years.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 6:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Boston Scientific Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance signals slower growth and operational challenges, likely prompting a sell‑off or caution among traders.

02

Market read

First report of Boston Scientific's earnings and guidance, a primary earnings disclosure with material impact on the stock.

03

What to watch

New product launches (Nalu, AGENT balloon) and the Penumbra acquisition may offset near‑term headwinds.

Relevance 8/10Novelty 8/10Timing: today

Background

The article summarizes Boston Scientific's Q3 earnings call, providing detailed segment performance and FY2026 outlook.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific disclosed Q3 results and FY2026 guidance, including organic revenue growth of ~3.75% and adjusted EPS of $3.16‑$3.18.

Expected impact

likely downside as investors price in slower growth and 2027 pressure

Evidence & confidence

The new guidance is lower than prior expectations and flags operational challenges, which typically depress the stock.

Market effects

Sector

Medical device sector may see broader scrutiny on electrophysiology and left‑atrial closure markets.

Regional

U.S. healthcare stocks could face modest pressure in the short term.

Global

Limited; impact confined to U.S. med‑tech equities.

Counterpoint

What could challenge this read

Restructuring savings of $500M could eventually boost margins, offering a longer‑term upside.

Key entities

  • company
    Boston Scientific

    Medical device manufacturer reporting earnings and guidance.

Read at source← All news

StoryBoston Scientific reports Q3 2026 results and cuts FY2026 outlook after cyberattack

Also covered by

5 outlets

Related articles

OCT 29
$BSXHighAI 8/10

Key facts: BSX Q3; EPS cut; China, EP/Watchman weak; Penumbra Q1'27

Boston Scientific (BSX) reported Q3 sales of $5.138B, up 1.5% YoY, with adjusted EPS of $0.73. The company cut FY2026 adjusted EPS guidance to $3.16–3.18, citing China pricing pressure and weakness in EP/Watchman devices. BSX expects Q4 sales to decline 1%–3%. The $14.5B Penumbra acquisition is delayed to Q1 2027 due to regulatory and financing issues. Needham maintained a Buy rating with a $48 target.

tradingview.com1 min
OCT 29
$BSXHigh

BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook

Boston Scientific (BSX) stock may end a 3-week rally as analysts downgrade it post-Q3 results and a weaker 2026 outlook. Jefferies and JPMorgan cut price targets to $46, citing cyberattack fallout, slowing growth, and delayed product pipelines. BSX reduced its full-year earnings forecast to $3.16-$3.18 per share from $3.28-$3.32. The stock is down 7% this week and 55% year-to-date.

stocktwits.com2 min
OCT 28
$MULow

Wall Street ends higher as Fed holds key rate steady, focus turns to earnings

US stock indices rose after the Fed kept rates unchanged, upgrading its economic outlook but noting elevated inflation. Markets anticipate a December rate hike, with 84% of S&P 500 companies beating earnings estimates. Micron Technology and SK Hynix shares jumped on strong earnings reports. Microsoft and Alphabet are set to report results. Vertiv rose on raised forecasts, while Boston Scientific fell on a profit forecast cut.

businesstimes.com.sg2 min
OCT 28
$BSXHighAI 8/10

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) fell 5.81% to $42.44 after cutting Q4 and full-year guidance due to a cyberattack. The company reported 1.5% sales growth and $0.73 adjusted EPS for Q3, missing estimates. Management expects a slow recovery, with 3.75% sales growth projected for 2026. Trading volume was 66.8M shares, 234% above average. The S&P 500 and Nasdaq Composite both rose slightly.

finance.yahoo.com2 min